while siRNA medicines require complex manufacturing at industrial scale.
RLT, a cutting-edge cancer treatment, is perhaps the most demanding example. It pairs a targeting ligand with a radioisotope to deliver precise radiation targeting cancer cells in the body. And, because the isotope decays quickly, teams are working against time from the moment manufacturing begins.
“ We made a bold bet on RLT eight years ago because we saw its potential to become a foundational pillar of cancer care. We started small with a few patients and a few centres,” Steffen reflects.“ Now, we supply RLT to patients worldwide, when and where they need it.”
Steffen adds that what makes RLT a particularly unique therapy is that it is personalised and individually prepared for each patient.“ From the moment you start manufacturing RLT, the clock starts ticking. We need to ensure the correct radioactive dose arrives with the patient at the right time” he adds.“ And from start to finish, this all needs to happen in three to five days. We serve patients in remote locations like Hawaii, with treatment made on the US mainland – when you map
manufacturingdigital. com 97